A pilot, double‐blind, placebo‐controlled trial of pregabalin (Lyrica) in the treatment of essential tremor
Identifieur interne : 002695 ( Main/Curation ); précédent : 002694; suivant : 002696A pilot, double‐blind, placebo‐controlled trial of pregabalin (Lyrica) in the treatment of essential tremor
Auteurs : Theresa A. Zesiewicz [États-Unis] ; Christopher L. Ward [États-Unis] ; Robert A. Hauser [États-Unis] ; Jason L. Salemi [États-Unis] ; Shaila Siraj [États-Unis] ; Maria-Carmen Wilson [États-Unis] ; Kelly L. Sullivan [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2007-08-15.
English descriptors
- KwdEn :
Abstract
We performed a pilot, double‐blind, placebo‐controlled, randomized trial to evaluate the efficacy and tolerability of pregabalin (PGB, Lyrica), an antiepileptic agent, in treating essential tremor (ET). Twenty two patients with ET were randomly assigned to receive PGB or placebo. PGB was initiated at 50 mg/day and was escalated by 75 mg/day every 4 days to a maximum dose of 600 mg/day. Patients were evaluated by accelerometry and the Fahn–Tolosa–Marin (FTM) rating scale. There was a significant reduction in tremor amplitude in the PGB group compared with the placebo group, as measured by accelerometry, at a mean dose of 286.76 ± 100.05 mg/day. Action tremor limb scores on the FTM also improved in the PGB group compared with the placebo group (P‐value for multilevel modeling = 0.04). PGB was fairly well tolerated, with about one‐third of patients dropping out of the study because of adverse events. PGB provided significant improvements in accelerometry and in action tremor limb scores on the FTM. However, larger studies are needed to further evaluate the potential effect of PGB on ET. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21629
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002A53
Links to Exploration step
ISTEX:552DF6F3F874F4E834C63BDF4AE4DEE779D090E3Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A pilot, double‐blind, placebo‐controlled trial of pregabalin (Lyrica) in the treatment of essential tremor</title>
<author><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name>
<affiliation wicri:level="1"><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ward, Christopher L" sort="Ward, Christopher L" uniqKey="Ward C" first="Christopher L." last="Ward">Christopher L. Ward</name>
<affiliation wicri:level="1"><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="1"><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Salemi, Jason L" sort="Salemi, Jason L" uniqKey="Salemi J" first="Jason L." last="Salemi">Jason L. Salemi</name>
<affiliation wicri:level="1"><mods:affiliation>Birth Defects Surveillance Program, Department of Pediatrics, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Birth Defects Surveillance Program, Department of Pediatrics, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Siraj, Shaila" sort="Siraj, Shaila" uniqKey="Siraj S" first="Shaila" last="Siraj">Shaila Siraj</name>
<affiliation wicri:level="1"><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wilson, Maria Armen" sort="Wilson, Maria Armen" uniqKey="Wilson M" first="Maria-Carmen" last="Wilson">Maria-Carmen Wilson</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Sullivan, Kelly L" sort="Sullivan, Kelly L" uniqKey="Sullivan K" first="Kelly L." last="Sullivan">Kelly L. Sullivan</name>
<affiliation wicri:level="1"><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:552DF6F3F874F4E834C63BDF4AE4DEE779D090E3</idno>
<date when="2007" year="2007">2007</date>
<idno type="doi">10.1002/mds.21629</idno>
<idno type="url">https://api.istex.fr/document/552DF6F3F874F4E834C63BDF4AE4DEE779D090E3/fulltext/pdf</idno>
<idno type="wicri:Area/Main/Corpus">002A53</idno>
<idno type="wicri:Area/Main/Curation">002695</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A pilot, double‐blind, placebo‐controlled trial of pregabalin (Lyrica) in the treatment of essential tremor</title>
<author><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name>
<affiliation wicri:level="1"><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ward, Christopher L" sort="Ward, Christopher L" uniqKey="Ward C" first="Christopher L." last="Ward">Christopher L. Ward</name>
<affiliation wicri:level="1"><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="1"><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Salemi, Jason L" sort="Salemi, Jason L" uniqKey="Salemi J" first="Jason L." last="Salemi">Jason L. Salemi</name>
<affiliation wicri:level="1"><mods:affiliation>Birth Defects Surveillance Program, Department of Pediatrics, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Birth Defects Surveillance Program, Department of Pediatrics, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Siraj, Shaila" sort="Siraj, Shaila" uniqKey="Siraj S" first="Shaila" last="Siraj">Shaila Siraj</name>
<affiliation wicri:level="1"><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wilson, Maria Armen" sort="Wilson, Maria Armen" uniqKey="Wilson M" first="Maria-Carmen" last="Wilson">Maria-Carmen Wilson</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Sullivan, Kelly L" sort="Sullivan, Kelly L" uniqKey="Sullivan K" first="Kelly L." last="Sullivan">Kelly L. Sullivan</name>
<affiliation wicri:level="1"><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2007-08-15">2007-08-15</date>
<biblScope unit="volume">22</biblScope>
<biblScope unit="issue">11</biblScope>
<biblScope unit="page" from="1660">1660</biblScope>
<biblScope unit="page" to="1663">1663</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">552DF6F3F874F4E834C63BDF4AE4DEE779D090E3</idno>
<idno type="DOI">10.1002/mds.21629</idno>
<idno type="ArticleID">MDS21629</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Lyrica</term>
<term>essential tremor</term>
<term>pregabalin</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="fr">We performed a pilot, double‐blind, placebo‐controlled, randomized trial to evaluate the efficacy and tolerability of pregabalin (PGB, Lyrica), an antiepileptic agent, in treating essential tremor (ET). Twenty two patients with ET were randomly assigned to receive PGB or placebo. PGB was initiated at 50 mg/day and was escalated by 75 mg/day every 4 days to a maximum dose of 600 mg/day. Patients were evaluated by accelerometry and the Fahn–Tolosa–Marin (FTM) rating scale. There was a significant reduction in tremor amplitude in the PGB group compared with the placebo group, as measured by accelerometry, at a mean dose of 286.76 ± 100.05 mg/day. Action tremor limb scores on the FTM also improved in the PGB group compared with the placebo group (P‐value for multilevel modeling = 0.04). PGB was fairly well tolerated, with about one‐third of patients dropping out of the study because of adverse events. PGB provided significant improvements in accelerometry and in action tremor limb scores on the FTM. However, larger studies are needed to further evaluate the potential effect of PGB on ET. © 2007 Movement Disorder Society</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002695 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 002695 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonV1 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:552DF6F3F874F4E834C63BDF4AE4DEE779D090E3 |texte= A pilot, double‐blind, placebo‐controlled trial of pregabalin (Lyrica) in the treatment of essential tremor }}
This area was generated with Dilib version V0.6.23. |